CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
News Sep 07, 2007
CODA Genomics has announced that the US Patent and Trademark Office has issued US Patent 7,262,031 to its two founding scientists, University of California, Irvine (UCI) professors, Richard H. Lathrop and G. Wesley Hatfield.
The technology was developed under an Information Technology Research grant from the National Science Foundation jointly in the School of Medicine and the Donald Bren School of Information and Computer Sciences at UCI. The Company has licensed this patent exclusively from the UCI’s Office of Technology Assessment (OTA).
US Patent 7,262,031 entitled, “Method for Producing a Synthetic Gene or Other DNA Sequence,” teaches how to use a global (across all possible correct and incorrect gene assemblies) optimization method for the choice of DNA code to make a given protein. Properly chosen DNA enables the thermodynamically controlled self-assembly of only the desired DNA product(s). The synthetic gene is simultaneously optimized for many other parameters that affect the successful use of the gene to make protein efficiently in any desired biological system.
Robert J Molinari, Ph.D., CODA’s CEO said, “This broad protection of CODA’s breakthrough technology will allow the company to aggressively market its high-yielding Hot- Rod™ genes, and other optimized gene variant sets. For the customer, it allows a scaleable way to test a large number of gene and protein variants for desirable properties.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.